Molecular Pathology Testing in Estimate Prognosis in Cancer
Voting Questions
March 24, 2015

	For the voting questions, use the following scale identifying level of confidence - with 1 being the lowest or no confidence and 5 representing a high level of confidence.	Burke	Fischer	Grant	Guadagnolo	Kamrava	Salive	Scheuner	Zuckerman	Ramamurthy	Berger	Voting Member Average	Overall Average
1a.	For each molecular pathology test listed below, how confident are you that existing evidence is sufficient to confirm the analytical validity of the molecular pathology test to estimate prognosis for Medicare beneficiaries with that cancer type?												
	1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence												
	For each prognostic test, if the average of voting members' answers for Question 1a. is at least in the 'Intermediate' range (mean score is 2.5 or more) please vote on Question 1b.												
	Adenocarcinoma of the Colon and Rectum												
	BRAF	2	2	4	4	4	5	1	2	1	5	**3.00**	**3.00**
	KRAS	2	2	4	4	4	4	5	4	4	4	**3.63**	**3.70**
	Microsatellite Instability	3	3	4	4	4	4	5	3	4	4	**3.75**	**3.80**
	MLH1 Promoter Methylation	2	2	4	4	4	1	1	1	2	2	**2.38**	**2.31**
	Oncotype DX® Colon	2	3	4	4	4	4	3	1	2	4	**3.13**	**3.10**
	Breast Cancer (Invasive Duct and Lobular Cancers)												
	MammaPrint®	3	2	5	3	4	5	5	2	5	4	**3.63**	**3.80**
	Oncotype DX® Breast	3	5	5	4	4	4	5	2	5	4	**4.00**	**4.10**
	Non-Small Cell Lung Cancers												
	ALK	1	1	4	3	4	4	2	1	4	4	**2.50**	**2.80**
	EGFR	2	2	4	4	4	1	1	3	4	4	**2.63**	**2.90**
	KRAS	2	4	3	4	4	4	4	4	2	4	**3.63**	**3.50**

Molecular Pathology Testing in Estimate Prognosis in Cancer
Voting Questions
March 24, 2015

	For the voting questions, use the following scale identifying level of confidence - with 1 being the lowest or no confidence and 5 representing a high level of confidence.	Burke	Fischer	Grant	Guadagnolo	Kamrava	Salive	Scheuner	Zuckerman	Ramamurthy	Berger	Voting Member Average	Overall Average
1b.	For each molecular pathology test listed below, how confident are you that existing evidence is sufficient to confirm the clinical validity of the molecular pathology test to estimate prognosis in Medicare beneficiaries with that cancer type?												
	1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence												
	For each prognostic test, if the average of voting members' answers for Question 1b. is at least in the 'Intermediate' range (mean score is 2.5 or more) please vote on Question 2.												
	Adenocarcinoma of the Colon and Rectum												
	BRAF	1	1	3	4	4	3	5	2	2	4	**2.88**	**2.90**
	KRAS	1	3	2	3	2	3	5	3	3	3	**2.75**	**2.80**
	Microsatellite Instability	2	2	4	4	4	3	5	3	4	5	**3.38**	**3.60**
	MLH1 Promoter Methylation - **The mean vote on this prognostic test from question 1a. was less than 2.5 so the panel members did not vote on this prognostic test.**												
	Oncotype DX® Colon	1	2	2	2	2	1	2	1	1	1	**1.63**	**1.50**
	Breast Cancer (Invasive Duct and Lobular Cancers)												
	MammaPrint®	3	1	3	3	4	3	4	3	5	4	**3.00**	**3.30**
	Oncotype DX® Breast	3	4	4	4	4	4	5	3	4	4	**3.88**	**3.90**
	Non-Small Cell Lung Cancers												
	ALK	1	1	1	1	2	3	1	1	2	1	**1.38**	**1.40**
	EGFR	1	3	1	2	2	1	1	1	2	1	**1.50**	**1.50**
	KRAS	2	4	1	4	2	2	3	1	2	2	**2.38**	**2.30**

Molecular Pathology Testing in Estimate Prognosis in Cancer
Voting Questions
March 24, 2015

	For the voting questions, use the following scale identifying level of confidence - with 1 being the lowest or no confidence and 5 representing a high level of confidence.	Burke	Fischer	Grant	Guadagnolo	Kamrava	Salive	Scheuner	Zuckerman	Ramamurthy	Berger	Voting Member Average	Overall Average
2	How confident are you that there is sufficient evidence to conclude that using the molecular pathology test to estimate prognosis **affects** health outcomes (including benefits and harms and change in management) for Medicare beneficiaries with cancer whose anti-cancer treatment strategy is guided by the test's result?												
	1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence												
	For each prognostic test, if the average of voting members' answers for Questions 1a and 1b are both in the 'Intermediate' range (mean score is 2.5 or more) please vote on Question 2.												
	Adenocarcinoma of the Colon and Rectum												
	BRAF	1	2	3	2	3	2	3	3	3	2	**2.38**	**2.40**
	KRAS	1	3	1	2	3	2	3	2	4	3	**2.13**	**2.40**
	Microsatellite Instability	2	3	4	4	3	2	4	3	4	4	**3.13**	**3.30**
	MLH1 Promoter Methylation - **The mean vote on this prognostic test from question 1a. was less than 2.5 so the panel members did not vote on this prognostic test for questions 1b. or 2.**												
	Oncotype DX® Colon - **The mean vote on this prognostic test from question 1b. was less than 2.5 so the panel members did not vote on this prognostic test.**												
	Breast Cancer (Invasive Duct and Lobular Cancers)												
	MammaPrint®	2	2	3	4	4	3	2	2	4	4	**2.75**	**3.00**
	Oncotype DX® Breast	2	4	4	3	4	1	4	2	4	4	**3.00**	**3.20**
	Non-Small Cell Lung Cancers												
	ALK - **The mean vote on this prognostic test from question 1b. was less than 2.5 so the panel members did not vote on this prognostic test.**												
	EGFR - **The mean vote on this prognostic test from question 1b. was less than 2.5 so the panel members did not vote on this prognostic test.**												
	KRAS - **The mean vote on this prognostic test from question 1b. was less than 2.5 so the panel members did not vote on this prognostic test.**												

Molecular Pathology Testing in Estimate Prognosis in Cancer
Voting Questions
March 24, 2015

	For the voting questions, use the following scale identifying level of confidence - with 1 being the lowest or no confidence and 5 representing a high level of confidence.	Burke	Fischer	Grant	Guadagnolo	Kamrava	Salive	Scheuner	Zuckerman	Ramamurthy	Berger	Voting Member Average	Overall Average
3	How confident are you that there is sufficient evidence to conclude that using the molecular pathology test to estimate prognosis has clinical utility (meaning, that it *improves* health outcomes either due to increased benefits and/or reduced harms) for Medicare beneficiaries with cancer whose anti-cancer treatment strategy is guided by the test's result?												
	1 Low Confidence -2- 3 Intermediate Confidence -4- 5 High Confidence												
	For each prognostic test, if the average of voting members' answers for Question 2 is in the 'Intermediate' range (mean score is 2.5 or more) please vote on Question 3.												
	Adenocarcinoma of the Colon and Rectum												
	BRAF - **The mean vote on this prognostic test from question 2 was less than 2.5 so the panel members did not vote on this prognostic test.**												
	KRAS - **The mean vote on this prognostic test from question 2 was less than 2.5 so the panel members did not vote on this prognostic test.**												
	Microsatellite Instability	1	3	3	3	1	1	3	2	3	3	**2.13**	**2.30**
	MLH1 Promoter Methylation - **The mean vote on this prognostic test from question 1a. was less than 2.5 so the panel members did not vote on this prognostic test for questions 1b., 2 or 3.**												
	Oncotype DX® Colon - **The mean vote on this prognostic test from question 1b. was less than 2.5 so the panel members did not vote on this prognostic test for questions 2 or 3.**												
	Breast Cancer (Invasive Duct and Lobular Cancers)												
	MammaPrint®	2	2	2	3	2	3	2	2	4	4	**2.25**	**2.60**
	Oncotype DX® Breast	2	4	3	3	2	4	3	2	4	4	**2.88**	**3.10**
	Non-Small Cell Lung Cancers												
	ALK - **The mean vote on this prognostic test from question 1b. was less than 2.5 so the panel members did not vote on this prognostic test for questions 2 or 3.**												
	EGFR - **The mean vote on this prognostic test from question 1b. was less than 2.5 so the panel members did not vote on this prognostic test for questions 2 or 3.**												
	KRAS - **The mean vote on this prognostic test from question 1b. was less than 2.5 so the panel members did not vote on this prognostic test for questions 2 or 3.**												